Abstract:Background: The study of high-throughput genomic profiles from a pharmacogenomics viewpoint has provided unprecedented insights into the oncogenic features modulating drug response. A recent study screened for the response of a thousand human cancer cell lines to a wide collection of anti-cancer drugs and illuminated the link between cellular genotypes and vulnerability. However, due to essential differences between cell lines and tumors, to date the translation into predicting drug response in tumors remains challenging. Recently, advances in deep learning have revolutionized bioinformatics and introduced new techniques to the integration of genomic data. Its application on pharmacogenomics may fill the gap between genomics and drug response and improve the prediction of drug response in tumors. Results: We proposed a deep learning model to predict drug response (DeepDR) based on mutation and expression profiles of a cancer cell or a tumor. The model contains three deep neural networks (DNNs), i) a mutation encoder pre-trained using a large pan-cancer dataset (The Cancer Genome Atlas; TCGA) to abstract core representations of high-dimension mutation data, ii) a pre-trained expression encoder, and iii) a drug response predictor network integrating the first two subnetworks. Given a pair of mutation and expression profiles, the model predicts IC50 values of 265 drugs. We trained and tested the model on a dataset of 622 cancer cell lines and achieved an overall prediction performance of mean squared error at 1.96 (log-scale IC50 values). The performance was superior in prediction error or stability than two classical methods (linear regression and support vector machine) and four analog DNN models of DeepDR, including DNNs built without TCGA pre-training, partly replaced by principal components, and built on individual types of input data. We then applied the model to predict drug response of 9059 tumors of 33 cancer types. Using per-cancer and pan-cancer settings, the model predicted both known, including EGFR inhibitors in non-small cell lung cancer and tamoxifen in ER+ breast cancer, and novel drug targets, such as vinorelbine for TTN-mutated tumors. The comprehensive analysis further revealed the molecular mechanisms underlying the resistance to a chemotherapeutic drug docetaxel in a pan-cancer setting and the anti-cancer potential of a novel agent, CX-5461, in treating gliomas and hematopoietic malignancies. Conclusions: Here we present, as far as we know, the first DNN model to translate pharmacogenomics features identified from in vitro drug screening to predict the response of tumors. The results covered both well-studied and novel mechanisms of drug resistance and drug targets. Our model and findings improve the prediction of drug response and the identification of novel therapeutic options.

Integration of autoencoder and graph convolutional network for predicting breast cancer drug response

GADRP: graph convolutional networks and autoencoders for cancer drug response prediction

Predicting cancer drug response using parallel heterogeneous graph convolutional networks with neighborhood interactions

DualGCN: a dual graph convolutional network model to predict cancer drug response

Improving anti-cancer drug response prediction using multi-task learning on graph convolutional networks

Deep learning assisted multi-omics integration for survival and drug-response prediction in breast cancer

Prior to Initiation of Chemotherapy, Can We Predict Breast Tumor Response? Deep Learning Convolutional Neural Networks Approach Using a Breast MRI Tumor Dataset

Predicting Drug Response Based on Multi-Omics Fusion and Graph Convolution

An Ensemble Learning Approach for Cancer Drug Prediction

Improving drug response prediction based on two-space graph convolution

Synergistic Drug Combination Prediction by Integrating Multi-omics Data in Deep Learning Models

The prediction of drug sensitivity by multi-omics fusion reveals the heterogeneity of drug response in pan-cancer

DeepDRA: Drug repurposing using multi-omics data integration with autoencoders

DRN-CDR: A cancer drug response prediction model using multi-omics and drug features

DeepCDR: a Hybrid Graph Convolutional Network for Predicting Cancer Drug Response

Predicting drug activity against cancer through genomic profiles and SMILES

An Improved Anticancer Drug-Response Prediction Based on an Ensemble Method Integrating Matrix Completion and Ridge Regression

Predicting drug response of tumors from integrated genomic profiles by deep neural networks

Developing Anticancer Drug Response System Using Deep Learning System with Hybrid Genomic and Chemical Features

Deep graph embedding for prioritizing synergistic anticancer drug combinations

Variational Autoencoder for Anti-Cancer Drug Response Prediction